A detailed history of Vanguard Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,468,755 shares of RCUS stock, worth $87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,468,755
Previous 5,257,326 4.02%
Holding current value
$87 Million
Previous $80.1 Million 4.43%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.69 - $18.01 $2.89 Million - $3.81 Million
211,429 Added 4.02%
5,468,755 $83.6 Million
Q2 2024

Aug 13, 2024

BUY
$14.59 - $18.48 $6.8 Million - $8.61 Million
466,082 Added 9.73%
5,257,326 $80.1 Million
Q1 2024

May 10, 2024

BUY
$14.83 - $20.18 $1.64 Million - $2.23 Million
110,528 Added 2.36%
4,791,244 $90.5 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $2.51 Million - $3.67 Million
186,898 Added 4.16%
4,680,716 $89.4 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $1.08 Million - $1.44 Million
61,040 Added 1.38%
4,493,818 $80.7 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $154,749 - $200,891
9,119 Added 0.21%
4,432,778 $90 Million
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $805,692 - $1.17 Million
50,482 Added 1.15%
4,423,659 $80.7 Million
Q4 2022

Feb 10, 2023

SELL
$19.7 - $35.71 $1.65 Million - $3 Million
-84,007 Reduced 1.88%
4,373,177 $90.4 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $4.04 Million - $5.23 Million
173,854 Added 4.06%
4,457,184 $117 Million
Q2 2022

Aug 12, 2022

BUY
$17.23 - $37.73 $13.3 Million - $29.1 Million
771,216 Added 21.96%
4,283,330 $109 Million
Q1 2022

May 13, 2022

BUY
$28.92 - $41.83 $2.48 Million - $3.59 Million
85,778 Added 2.5%
3,512,114 $111 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $30.1 Million - $46.5 Million
959,857 Added 38.92%
3,426,336 $139 Million
Q3 2021

Nov 12, 2021

BUY
$26.93 - $37.68 $996 - $1,394
37 Added 0.0%
2,466,479 $86 Million
Q2 2021

Aug 13, 2021

BUY
$22.75 - $35.77 $56.1 Million - $88.2 Million
2,466,442 New
2,466,442 $67.7 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.